Thus, MEK and mTOR co-targeting may represent a successful, generalized targeting strategy against diverse BRAF-fusions that warrants careful testing in PLGGs as well as other pediatric and adult cancers where additional BRAF-fusions are being discovered. Here, BRAF is linked to cancer.